Highlights Jaguar Health, Inc.

Equities

JAGX

US47010C7065

Market Closed - Nasdaq Other stock markets 21:00:00 13/05/2024 BST			After market 00:49:26
0.2903 ^USD	-0.62%		0.286	-1.48%

05-06	Jaguar Health Applies for Investigational New Animal Drug Status for Potential Dog Diarrhea Treatment	MT
05-06	Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration	05-06	CI
Venture Life renews revolving credit facility with Santander and HSBC	04-19	AN
Wall Street Set to Open Sharply Lower Wednesday as Inflation Rises More Than Expected	04-10	MT
Exchange-Traded Funds Down, Equity Futures Higher Pre-Bell Wednesday Ahead of Fed Meeting Minutes	04-10	MT
Top Premarket Gainers	04-10	MT
Jaguar Health, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Jaguar Health Reaches Agreement With FDA on Design, Conduct of Medicine Study	02-15	MT
Jaguar Health, Inc. Announces FDA Agrees with Clinical Trial Protocol for Full Approval of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea in Dogs	02-15	CI
Napo Pharmaceuticals, Inc. Announces Majority of Subjects in Placebo-Controlled Pivotal Phase 3 OnTarget Trial for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Therapy Chose to Continue on to Continue on to Stage II	12-11	CI
FDA Approves Renewal of Canalevia-CA1, Jaguar Health?s Drug for Chemotherapy-Induced Diarrhea in Dogs	12-04	CI
Jaguar Health, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Jaguar Health Gets Additional 180-Day Grace Period to Regain Nasdaq Compliance	11-08	MT
Jaguar Health, Inc. Announces Issuance of New US Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome	11-01	CI
Earnings Flash (JAGX) JAGUAR HEALTH Reports Q2 Revenue $2.7M	14/08/23	MT
Jaguar Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Jaguar Health, Inc. Announces the Results of an Independent Pilot Phase 2 Study of Crofelemer for the Management ofneratinib-Associated Diarrhea	07/08/23	CI
Jaguar Health Says FDA Activates Third-Party Investigational New Drug Application for Crofelemer	01/08/23	MT
Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome	01/08/23	CI
Jaguar Health Unit Submits Investigational New Drug Application to FDA for Therapy to Treat Microvillus Inclusion Disease	28/06/23	MT
Napo Pharmaceuticals Submits Investigational New Drug Application to FDA for MicroVillus Inclusion Disease	28/06/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Jaguar Health, Inc.

Equities

JAGX

US47010C7065

Highlights

Filters